+357 96 030922
info@marketpublishers.com

On-body Injectors Market Size, Share and Growth Outlook 2026: By Technology (Spring-based Injectors, Motor-driven Injectors, Rotary Pump Injectors, Expanding Battery / Osmotic Injectors), By Type, By Application, By End-User, Companies to 2034.

https://marketpublishers.com/r/O88400773B4EEN.html
Date: July 2026
Pages: 190
Price: US$ 3,482.00 (Single User License)
ID: O88400773B4EEN

Abstracts

The global On-body Injectors Market size is forecast to increase from $7.7 Billion in 2026 to $24.34 Billion in 2034 at a CAGR of 15.47% between 2026 and 2034.

The On-body Injectors market report provides detailed analysis and outlook of On-body Injectors segments including By Technology (Spring-based Injectors, Motor-driven Injectors, Rotary Pump Injectors, Expanding Battery / Osmotic Injectors), By Type (Smart / Connected On-body Injectors (Bluetooth/IoT enabled), Conventional On-body Injectors), By Application (Diabetes, Oncology, Autoimmune Diseases, Cardiovascular Diseases), By End-User (Home Care Settings, Hospitals and Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

On-body Injectors Industry Overview

Home-Based Biologic Delivery Is Reshaping the On-body Injectors Market

The on-body injectors (OBI) industry is rapidly transforming drug administration by enabling large-volume biologic therapies to be delivered safely outside conventional infusion centers. Pharmaceutical companies and device manufacturers are increasingly developing wearable injection platforms that improve patient convenience, reduce hospital dependence, and support long-duration therapies through subcutaneous administration. Growing biologic pipelines, rising healthcare cost optimization initiatives,

+357 96 030922
info@marketpublishers.com

and the shift toward patient-centered care are accelerating demand for injector systems capable of delivering high-viscosity formulations while maintaining dosing accuracy, treatment adherence, and user-friendly operation in home and outpatient environments.

Large-Volume Wearable Technologies Are Expanding Therapeutic Applications

A defining trend across the industry is the commercialization of wearable injectors designed for increasingly complex biologic medicines. This transition is demonstrated by the European Commission's approval of the subcutaneous formulation of Sanofi's Sarclisa (isatuximab), making it the first anticancer therapy in the European Union to be administered through an on-body injector. The approval enables eligible patients to receive treatment in outpatient clinics or home settings instead of conventional intravenous infusion centers, illustrating the broader migration toward decentralized oncology care. Simultaneously, Enable Injections' enFuse® platform continues to gain traction across pharmaceutical development pipelines by supporting the subcutaneous administration of large-volume biologics that traditionally required lengthy intravenous infusions. These wearable systems are enabling pharmaceutical developers to improve treatment accessibility while enhancing patient comfort and adherence.

High-Viscosity Drug Delivery Is Driving Device Innovation

The rapid expansion of biologics is creating strong demand for next-generation injector platforms capable of handling increasingly challenging drug formulations. Industry development efforts are focused on wearable injectors engineered to administer high-viscosity therapeutics and large-volume doses of 5 mL or greater while maintaining injection precision and patient comfort. Manufacturers are optimizing mechanical delivery systems, injection control technologies, and ergonomic wearable designs to accommodate evolving biologic pipelines across oncology, immunology, and chronic disease management. As healthcare systems continue shifting toward self-administration and home-based treatment models, on-body injectors are becoming essential components of modern drug delivery strategies by reducing dependence on infusion centers, improving operational efficiency, and expanding access to advanced biologic therapies.

On-body Injectors Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global On-body Injectors market is witnessing increasing investments in innovation,

+357 96 030922
info@marketpublishers.com

product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Becton, Dickinson and Company, Insulet Corporation, West Pharmaceutical Services, Inc., Ypsomed AG, Enable Injections, Debiotech SA, Sonceboz, Elcam Medical, Gerresheimer AG (Sensile Medical), CeQur SA. The On-body Injectors market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the On-body Injectors industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth On-body Injectors Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by On-body Injectors companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional On-body Injectors markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

On-body Injectors Market Competitive Benchmarking and Company Analysis

Leading companies in On-body Injectors industry include- Becton, Dickinson and

+357 96 030922
info@marketpublishers.com

Company, Insulet Corporation, West Pharmaceutical Services, Inc., Ypsomed AG, Enable Injections, Debiotech SA, Sonceboz, Elcam Medical, Gerresheimer AG (Sensile Medical), CeQur SA. The On-body Injectors market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US On-body Injectors Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the On-body Injectors market remains one of the strongest-performing segments in the country.

The US On-body Injectors Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US On-body Injectors market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across On-body Injectors industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian On-body Injectors markets

Canada's strong On-body Injectors sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-

+357 96 030922
info@marketpublishers.com

sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian On-body Injectors market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany On-body Injectors Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest On-body Injectors market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of On-body Injectors population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany On-body Injectors industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the On-body Injectors market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support On-body Injectors sales through 2034

France On-body Injectors companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were

+357 96 030922
info@marketpublishers.com

651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK On-body Injectors Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of On-body Injectors distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China On-body Injectors Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China On-body Injectors market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of On-body Injectors industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese On-body Injectors industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India On-body Injectors Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

+357 96 030922
info@marketpublishers.com

Indian On-body Injectors market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil On-body Injectors market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa On-body Injectors Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

On-body Injectors Market Segmentation

By Technology

Spring-based Injectors

+357 96 030922
info@marketpublishers.com

Motor-driven Injectors

Rotary Pump Injectors

Expanding Battery / Osmotic Injectors

By Type

Smart / Connected On-body Injectors (Bluetooth/IoT enabled)

Conventional On-body Injectors

By Application

Diabetes

Oncology

Autoimmune Diseases

Cardiovascular Diseases

By End-User

Home Care Settings

Hospitals and Clinics

Leading Companies in On-body Injectors Industry (2026)

Becton, Dickinson and Company

Insulet Corporation

West Pharmaceutical Services, Inc.

Ypsomed AG

Enable Injections

+357 96 030922
info@marketpublishers.com

Debiotech SA

Sonceboz

Elcam Medical

Gerresheimer AG (Sensile Medical)

CeQur SA

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and

+357 96 030922
info@marketpublishers.com

plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 8- EUROPE ON-BODY INJECTORS MARKET SIZE ANALYSIS AND OUTLOOK

+357 96 030922
info@marketpublishers.com

CHAPTER 9- ASIA PACIFIC ON-BODY INJECTORS MARKET SIZE ANALYSIS AND OUTLOOK

+357 96 030922
info@marketpublishers.com

CHAPTER 10- SOUTH AND CENTRAL AMERICA ON-BODY INJECTORS MARKET SIZE ANALYSIS AND OUTLOOK

+357 96 030922
info@marketpublishers.com

CHAPTER 11- MIDDLE EAST AND AFRICA ON-BODY INJECTORS MARKET SIZE ANALYSIS AND OUTLOOK

CHAPTER 12- COMPANY PROFILES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: On-body Injectors Market Size, Share and Growth Outlook 2026: By Technology (Spring-based Injectors, Motor-driven Injectors, Rotary Pump Injectors, Expanding Battery / Osmotic Injectors), By Type, By Application, By End-User, Companies to 2034.

Product link: https://marketpublishers.com/r/O88400773B4EEN.html

Price: US$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O88400773B4EEN.html